Bath Savings Trust Co Cuts Stock Holdings in Danaher Corporation $DHR

Key Points

• Bath Savings Trust Co sold 4,703 shares of Danaher Corporation (NYSE:DHR), reducing its position by 6.8% to a total of 64,876 shares, which are valued at approximately $12.8 million.
• Wall Street analysts maintain a generally positive outlook on Danaher, with an average rating of "Moderate Buy" and a price target averaging $246.35.
• Danaher plans to pay a quarterly dividend of $0.32 per share on October 31st, reflecting an annualized dividend yield of 0.7% and a payout ratio of 27.23%.

Bath Savings Trust Co cut its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 6.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 64,876 shares of the conglomerate's stock after selling 4,703 shares during the period. Danaher accounts for 1.3% of Bath Savings Trust Co's portfolio, making the stock its 24th largest holding. Bath Savings Trust Co's holdings in Danaher were worth $12,816,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. GHP Investment Advisors Inc. raised its position in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares during the period. Heck Capital Advisors LLC purchased a new stake in shares of Danaher in the fourth quarter worth $27,000. Sierra Ocean LLC increased its stake in shares of Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Danaher in the first quarter worth $31,000. Finally, Dunhill Financial LLC increased its stake in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after purchasing an additional 67 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 1.5%

DHR traded down $2.99 on Monday, reaching $190.30. 2,949,617 shares of the company traded hands, compared to its average volume of 3,371,563. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The firm has a fifty day simple moving average of $200.02 and a two-hundred day simple moving average of $198.03. The company has a market cap of $136.26 billion, a P/E ratio of 40.49, a price-to-earnings-growth ratio of 2.70 and a beta of 0.75. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the business posted $1.72 EPS. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio (DPR) is 27.23%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DHR. Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Guggenheim reiterated a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Wells Fargo & Company lowered their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average price target of $245.91.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 11.20% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.